Level Biotechnology

Level Biotechnology Gross Margin

The Gross Margin of Level Biotechnology (3118.TWO) as of Oct 17, 2026 is 34.99 %. In the previous year, Gross Margin was 32.42 % — a change of 7.90% (higher).

Gross Margin

34.99 %

YoY

7.90%

Last updated:

Gross Margin of Level Biotechnology is 2025 34.99 % . Gross Margin of Level Biotechnology was 2024 32.42 % . It decreases by 7.90% higher compared to the previous year.

Level Biotechnology's gross margin stands at 35.0%, broadly stable from 34.3% several years earlier.

The Level Biotechnology Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
29.49 TWD
Jan 1, 2019
30.65 TWD
Jan 1, 2020
31.48 TWD
Jan 1, 2021
34.33 TWD
Jan 1, 2022
34.16 TWD
Jan 1, 2023
33.23 TWD
Jan 1, 2024
32.42 TWD
Jan 1, 2025
34.99 TWD
The Level Biotechnology Gross Margin history
YEARGross MarginYoY
34.99 %+7.90%
32.42 %-2.44%
33.23 %-2.72%
34.16 %-0.48%
34.33 %+9.04%
31.48 %+2.73%
30.65 %+3.92%
29.49 %-18.08%
36.00 %-4.62%
37.74 %-3.49%
39.11 %+1.12%
38.68 %+10,619.44%
0.36 %-1.06%
0.36 %-3.40%
0.38 %+1.60%
0.37 %+1.77%
0.37 %-6.92%
0.39 %+3.53%
0.38 %+0.21%
0.38 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Level Biotechnology Stock analysis

What does Level Biotechnology do? Level Biotechnology Inc is a company based in Taipei, Taiwan, operating within the Health Care sector. It went public on September 10, 2004, with its ticker symbol 3118.TWO and ISIN TW0003118006. The company provides biotechnological services, focusing on products such as cell culture series, immune protein series, gene nucleic acid and molecular biology series, and instrument series. Additionally, Level Biotechnology offers preclinical testing services, including genetic toxicity testing, general toxicology testing, reproductive toxicology testing, pharmacokinetic testing, and biocompatibility testing. The company's website is https://www.level.com.tw/index_tw.php. Level Biotechnology operates primarily in the domestic market, serving clients within Taiwan. It is headquartered in Taipei, New Taipei, as stated in the provided information. The company's services and products are designed to support research and development in the biotechnology and health care fields. No additional details about founding year, key personnel, acquisitions, or specific financial figures are provided in the given data. The company's activities are centered around delivering specialized biotechnological solutions to its market. Level Biotechnology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Level Biotechnology stock

Gross Margin of Level Biotechnology is 34.99 % in 2025.

Gross Margin of Level Biotechnology changed from 32.42 % to 34.99 %, representing a 7.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Level Biotechnology since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Level Biotechnology with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Level Biotechnology

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Level Biotechnology